Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Pricing Drug Safety Clinical Trials Weight Loss Weight Loss Drugs Drug Regulation Cancer Treatment Medications

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

The once-daily therapy joins an emerging nonhormonal class with FDA-recommended liver tests at baseline and three months.

Novartis Posts Q3 Sales Rise but Misses Views, Reaffirms 2025 Outlook

Novartis to Buy Avidity Biosciences for $12 Billion, Adding Muscle-Targeted RNA Drugs

Report Says Rep. Jasmine Crockett Omitted Dozens of Stock Holdings and Debts

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case

FDA Lists Class II Recall of 141,984 Bottles of Generic Atorvastatin

Innovent Says Mazdutide Tops Semaglutide in China Phase 3 Diabetes Trial

New CMAJ Papers Highlight Rising Youth Opioid Harm as Prescribing Declines

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

Experts Press to Include Pregnant People in Drug Trials After Tylenol–Autism Claims

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

FDA Expands Revumenib Approval to NPM1-Mutant Relapsed/Refractory AML in Patients 1 and Older

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Inhibrx Drug Extends PFS in Chondrosarcoma Phase 2 as Shares Jump Over 70%

Oz Defends Trump’s Drug-Price Math on NBC as Fact-Checks Reject Claims of Cuts Over 100 Percent

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress

Ventyx’s NLRP3 Drug Cuts Inflammation Markers in Phase 2, Shares Soar

Cytokinetics Investors Urged to Seek Counsel Before Nov. 17 Lead-Plaintiff Deadline in Aficamten Case

Sanofi’s Efdoralprin Alfa Shows Superior Biomarker Response to Plasma Therapy in Phase 2 AATD Trial

Kenvue Asks FDA to Reject Autism Warning on Tylenol in Pregnancy